Emergent BioSolutions vs Telix Pharmaceuticals
Telix Pharmaceuticals reported revenue of $804 million in fiscal 2025, about the same as Emergent BioSolutions' $743 million in fiscal 2025. Emergent BioSolutions' revenue fell 28.8% in its latest year, and Telix Pharmaceuticals' grew 55.6%. Emergent BioSolutions had an operating margin of 13.5%, against 3.7% at Telix Pharmaceuticals. Free cash flow was $157 million at Emergent BioSolutions and −$43 million at Telix Pharmaceuticals.
Side by side
| Emergent BioSolutions | Telix Pharmaceuticals | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $743M | $804M |
| Revenue growth | −28.8% | 55.6% |
| Revenue growth a year, last 5 years | −14.0% | — |
| Gross margin | 56.1% | 53.0% |
| Operating margin | 13.5% | 3.7% |
| Net margin | 7.1% | −0.9% |
| Free cash flow | $157M | −$43M |
| Free cash flow margin | 21.1% | −5.3% |
| Return on capital | 6.4% | 5.0% |
| Net debt to EBITDA | 2.0x | 5.1x |
| Dividends and buybacks | $25M | $0M |
| Change in diluted share count | 7.0% | −2.1% |
| Last close | $5.15 | $8.71 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $840,301 | bought $1.0 million, sold $0 |
| Piotroski F-score | 7 of 9 | 2 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Emergent BioSolutionsTelix Pharmaceuticals
Operating margin
Percent of revenue
Emergent BioSolutionsTelix Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Emergent BioSolutionsTelix Pharmaceuticals
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Emergent BioSolutions and Telix Pharmaceuticals pages.